HWM
TEVA icon

HighMark Wealth Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

HighMark Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-400
Closed -$3K – 566
2022
Q3 		$3K Hold
400
– – ﹤0.01% 405
2022
Q2 		$3K Hold
400
– – ﹤0.01% 412
2022
Q1 		$4K Hold
400
– – ﹤0.01% 397
2021
Q4 		$3K Sell
400
-1,682
-81% -$15.2K ﹤0.01% 419
2021
Q3 		$20K Buy
2,082
+84
+4% +$787 0.01% 182
2021
Q2 		$20K Sell
1,998
-672
-25% -$7.11K 0.01% 188
2021
Q1 		$31K Sell
2,670
-644
-19% -$7.38K 0.02% 138
2020
Q4 		$32K Sell
3,314
-6,093
-65% -$58.4K 0.03% 129
2020
Q3 		$85K Buy
9,407
+7,252
+337% +$76.7K 0.08% 72
2020
Q2 		$27K Buy
2,155
+846
+65% +$9.57K 0.03% 114
2020
Q1 		$11K Hold
1,309
– – 0.01% 147
2019
Q4 		$12K Buy
+1,309
New +$11.7K 0.01% 182

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

HighMark Wealth Management's TEVA Position: Q4 2022 in Review

HighMark Wealth Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2022, closing a stake of 400 shares — an estimated $3K sold.

HighMark Wealth Management first reported a position in TEVA in Q4 2019 and held it in 12 quarters. The position peaked at $85K in Q3 2020. 421 funds tracked by Wall St. Rank hold TEVA as of Q4 2022.

  • HighMark Wealth Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2022 after selling out during the quarter.
  • HighMark Wealth Management sold 400 Teva Pharmaceutical Industries Limited shares in Q4 2022, an estimated $3K.
  • HighMark Wealth Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2019 and held it in 12 quarters.
  • HighMark Wealth Management's Teva Pharmaceutical Industries Limited position peaked at $85K in Q3 2020.
  • 421 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2022.

Based on HighMark Wealth Management's 13F filing for Q4 2022, filed 2 Feb 2023.